Management of Two TR-4 Thyroid Nodules
For two TR-4 thyroid nodules, determine if they meet size criteria for fine-needle aspiration (FNA): biopsy both nodules if they are ≥1.5 cm, or initiate ultrasound surveillance at 1,2,3, and 5 years if they are smaller. 1
Size-Based Decision Algorithm
The ACR TI-RADS guideline establishes clear size thresholds that drive management:
If both nodules are ≥1.5 cm: Proceed with FNA of both nodules. The ACR TI-RADS committee specifically recommends targeting no more than two nodules with the highest point totals that meet FNA criteria, which aligns perfectly with your scenario of two TR-4 nodules 1
If nodules are <1.5 cm: Initiate surveillance ultrasound protocol rather than immediate biopsy
Surveillance Protocol for Sub-Threshold Nodules
For TR-4 nodules below the 1.5 cm FNA threshold, follow this specific timeline:
- Year 1: First follow-up ultrasound
- Year 2: Second follow-up ultrasound
- Year 3: Third follow-up ultrasound
- Year 5: Final follow-up ultrasound 1
Stop surveillance at 5 years if no growth occurs, as stability over this timeframe reliably indicates benign behavior 1
Important Caveat on Small Nodules
Recent evidence suggests that TR-4 nodules below size thresholds still carry meaningful malignancy risk (20% in one study) 2. However, the established guideline framework prioritizes the 1.5 cm threshold to balance detection of clinically significant cancers against overdiagnosis of indolent disease 1.
What Constitutes Significant Growth
If nodules grow during surveillance, apply these specific criteria:
- 20% increase in at least two dimensions AND minimum 2 mm absolute increase, OR
- 50% or greater increase in volume 1
Critical point: Compare current measurements to the earliest available scan, not just the immediately preceding one, as growth may not be apparent with sequential-only comparison 1
If a nodule grows significantly but remains below 1.5 cm at 5 years, continued surveillance is warranted despite lack of published evidence for this scenario 1
Documentation Requirements
For proper tracking of your two nodules:
- Number each nodule sequentially (Nodule #1, Nodule #2)
- Document precise location (right/left lobe, upper/mid/lower pole, and if needed: anterior/posterior/medial/lateral)
- Measure in three axes: maximum axial dimension, perpendicular axial dimension, and maximum longitudinal dimension 1
- Include the nodule's halo in measurements if present 1
This meticulous documentation becomes essential when multiple nodules exist, preventing confusion on subsequent scans.
Why Not Biopsy Everything?
The guideline explicitly states that biopsying three or more nodules is poorly tolerated by patients, increases cost with little benefit, and adds risk 1. With two TR-4 nodules, you're at the recommended maximum for biopsy—but only if they meet the size threshold.
Size should not be the primary criterion—the ACR discourages using "dominant nodule" terminology for the largest lesion, as architecture (reflected in the TR score) takes precedence 1
Malignancy Context
TR-4 nodules carry moderate suspicion. Research shows that among nodules below biopsy thresholds that were biopsied anyway, TR-4 nodules had a 17.7% malignancy rate 3, while another study found 20% malignancy in TR-4 nodules <10 mm 2. However, these studies examined selected populations that underwent biopsy despite not meeting criteria, introducing selection bias. The guideline's size thresholds are designed to capture clinically significant cancers while avoiding overtreatment of indolent microcarcinomas 1.